Psychosis f-PG≥5.6 Psychosis f-PG<5.6 SDPP controls           Gene SNP Minor/major allele (aa/ab/bb)% (aa/ab/bb)% (aa/ab/bb)% Allelea OR [95% CI]b Pc BH FDRd Psychosis f-PG ≥5.6 vs Psychosis f-PG <5.6 IGF2BP2 rs4402960 T/G 8/45/47 13/48/39 12/40/48 G 1.39 [1.05-1.74] 0.019 0.76 Psychosis f-PG ≥5.6 vs SDPP controls NOTCH2 rs10923931 T/G 2/19/79 1/15/84 0/15/85 T 1.84 [1.13-2.46] 0.011 0.18   THADA rs7578597 C/T 2/11/87 <1/16/83 <1/19/80 T 1.81 [1.00-2.26] 0.014 0.18   WFS1 rs10010131 A/G 19/42/39 17/50/33 20/48/32 G 1.40 [1.03-1.69] 0.010 0.18   P2RX7 rs1718119 A/G 11/43/46 19/45/36 19/46/35 G  1.38 [1.21-1.89] 0.014 0.18   MTNR1B rs10830963 G/C 10/42/48 8/37/55 6/34/60 G 1.51 [1.16-1.89] 0.0039 0.17

aAllele associated with elevated fasting glucose in psychosis patients bOR calculated for the allele associated with hyperglycemia in psychosis patients cAdjusted for age, gender, smoking, waist circumference, and family history of diabetes dBenjamin Hochberg False discovery rate correction

Table 2: Allelic association with metabolic risk genes in psychosis patients with elevated fasting glucose, f-PG≥5.6 compared to psychosis patients with normal fasting plasma glucose (f-PG<5.6) and to SDPP controls.